Recent Developments:
In October 2020, Taconic Biosciences announced the launch of its first hACE2 model. AC70 mouse experiences a lethal response to SARS-CoV-2 (COVID-19). The new AC22 mouse is lethality-resistant, enabling therapeutic, vaccine, and post-infection symptom research.
In March 2020, Crown Bioscience launched two new liver fibrosis rodent models, allowing more rapid and cost- effective evaluation of the preclinical effects of NASH and anti-fibrotic treatments on acute liver injury, advanced fibrosis, and/or fibrosis reversal.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients